Our immune checkpoint activators protect patient’s organ tissue. Unique approach : - Potential for BEST-in-class super agonist against immune-mediated tissue damage - High selectivity for active T-cells - Proof of concept in relevant human in vitro models and mouse model of disease
Location: Germany, Hesse, Frankfurt
Employees: 1-10
Total raised: $661.5K
Investors 1
| Date | Name | Website |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.05.2023 | Pre-Seed | $661.5K | - |
Mentions in press and media 4
| Date | Title | Description |
| 05.05.2023 | Phialogics Raises €600K in Pre-Seed Financing | Phialogics, a Basel, Switzerland and Heidelberg, Germany-based startup which specializes in the field of autoimmune diseases, raised €600K in Pre-Seed funding. Backers included High-Tech Gründerfonds. The company intends to use the funds to... |
| 19.04.2023 | Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases | April 19, 2023 |
| 19.04.2023 | Phialogics closes 600,000 € pre-seed financing round | |
| - | Phialogics | “Home” |